Your browser doesn't support javascript.
loading
Orally available and efficacious α4ß1/α4ß7 integrin inhibitors.
Xu, Ying-zi; Smith, Jenifer L; Semko, Christopher M; Rossiter, Kassandra I; Fukuda, Juri Y; Dappen, Michael S; Quincy, David A; Konradi, Andrei W; Mao, Wenxian; Welch, Brent; Dreyer, Mark L; Samant, Bhushan; Zhang, Hongbin; Lugar, Judevin; Liao, Zhenmei; Henschel, Carrol; Petersen, Eric; Vandevert, Christopher; Shoemaker, Mark; Wehner, Nancy; Mutter, Linda; Shopp, George; Krimm, Michael; Chen, Linda; Wipke, Brian; Dofiles, Lilibeth; Gallager, Ian; Sauer, John-Michael; Messersmith, Elizabeth K; Pleiss, Michael A; Bard, Frederique; Yednock, Ted A.
Afiliação
  • Xu YZ; Elan Pharmaceuticals, 180 Oyster Point Blvd., South San Francisco, CA 94080, United States.
Bioorg Med Chem Lett ; 23(15): 4370-3, 2013 Aug 01.
Article em En | MEDLINE | ID: mdl-23777782
ABSTRACT
A series of potent α4ß1/α4ß7 integrin inhibitors is reported, including an inhibitor 12d with remarkable oral exposure and efficacy in rat models of rheumatoid arthritis and Crohn's disease.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Integrinas / Integrina alfa4beta1 Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2013 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Integrinas / Integrina alfa4beta1 Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2013 Tipo de documento: Article